We are investigating Mesoblast Limited (MESO) (“Mesoblast” or the “Company”) for potential violations of the federal securities laws. On August 11, 2020, the U.S. Food and Drug Administration (“FDA”) released briefing materials for the August 13, 2020 meeting of the FDA’s Oncologic Drugs Advisory Committee, at which the FDA will review and discuss Mesoblast’s marketing application for Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft-versus-host disease in pediatric patients. The FDA briefing documents stated that it is “unclear” whether the study results supporting Mesoblast’s application are “relevant” to the proposed indication for use. On this news, Mesoblast’s stock price fell $6.09 per share, or 34.96%, to close at $11.33 per share on August 11, 2020.